PF 4136309

Drug Profile

PF 4136309

Alternative Names: PF-04136309; PF-4136309

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Analgesics
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • Discontinued Hepatic fibrosis; Pain

Most Recent Events

  • 01 Apr 2016 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in USA (PO) (NCT02732938)
  • 01 Dec 2015 Phase-I clinical trials in Pancreatic cancer (In volunteers) in Belgium (PO) (NCT02598206)
  • 09 Nov 2015 Pfizer plans a phase I trial in Healthy volunteers in Belgium and USA (NCT02598206)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top